The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

James W. Welsh, Daruka Mahadevan, Ron Ellsworth, Laurence Cooke, David Bearss, Baldassarre Stea

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Purpose: Glioblastoma multiforme (GBM) is resistant to current cytotoxic therapies, in part because of enhanced DNA repair. Activation of the receptor tyrosine kinase c-Met has been shown to protect cancer cells from DNA damage. We hypothesized that inhibiting c-Met would decrease this protection and thus sensitize resistant tumor cells to the effects of radiation therapy.Materials and methods: Eight human GBM cell lines were screened for radiosensitivity to the small-molecule c-Met inhibitor MP470 with colony-count assays. Double-strand (ds) DNA breaks was quantified by using antibodies to gamma H2AX. Western blotting demonstrate expression of RAD51, glycogen synthase kinase (GSK)-3β, and other proteins. A murine xenograft tumor flank model was used for in vivo radiosensitization studies.Results: MP470 reduced c-Met phosphorylation and enhanced radiation-induced cell kill by 0.4 logs in SF767 cells. Cells pretreated with MP470 had more ds DNA damage than cells treated with radiation alone. Mechanistically, MP470 was shown to inhibit dsDNA break repair and increase apoptosis. MP470 influences various survival and DNA repair related proteins such as pAKT, RAD51 and GSK3β. In vivo, the addition of MP470 to radiation resulted in a tumor-growth-delay enhancement ratio of 2.9 over radiation alone and extended survival time.Conclusions: GBM is a disease site where radiation is often used to address both macroscopic and microscopic disease. Despite attempts at dose escalation outcomes remain poor. MP470, a potent small-molecule tyrosine kinase inhibitor of c-Met, radiosensitized several GBM cell lines both in vitro and in vivo, and may help to improve outcomes for patients with GBM.

Original languageEnglish (US)
Article number69
JournalRadiation Oncology
Volume4
Issue number1
DOIs
StatePublished - Dec 22 2009

Fingerprint

Proto-Oncogene Proteins c-met
Glioblastoma
Radiation
DNA Repair
DNA Damage
Neoplasms
Glycogen Synthase Kinase 3
Cell Line
Survival
Double-Stranded DNA Breaks
Radiation Tolerance
MP470
Heterografts
Protein-Tyrosine Kinases
Proteins
Radiotherapy
Western Blotting
Phosphorylation
Apoptosis
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. / Welsh, James W.; Mahadevan, Daruka; Ellsworth, Ron; Cooke, Laurence; Bearss, David; Stea, Baldassarre.

In: Radiation Oncology, Vol. 4, No. 1, 69, 22.12.2009.

Research output: Contribution to journalArticle

Welsh, James W. ; Mahadevan, Daruka ; Ellsworth, Ron ; Cooke, Laurence ; Bearss, David ; Stea, Baldassarre. / The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. In: Radiation Oncology. 2009 ; Vol. 4, No. 1.
@article{9b70878d79f24ef79c01fabab043d0ba,
title = "The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells",
abstract = "Purpose: Glioblastoma multiforme (GBM) is resistant to current cytotoxic therapies, in part because of enhanced DNA repair. Activation of the receptor tyrosine kinase c-Met has been shown to protect cancer cells from DNA damage. We hypothesized that inhibiting c-Met would decrease this protection and thus sensitize resistant tumor cells to the effects of radiation therapy.Materials and methods: Eight human GBM cell lines were screened for radiosensitivity to the small-molecule c-Met inhibitor MP470 with colony-count assays. Double-strand (ds) DNA breaks was quantified by using antibodies to gamma H2AX. Western blotting demonstrate expression of RAD51, glycogen synthase kinase (GSK)-3β, and other proteins. A murine xenograft tumor flank model was used for in vivo radiosensitization studies.Results: MP470 reduced c-Met phosphorylation and enhanced radiation-induced cell kill by 0.4 logs in SF767 cells. Cells pretreated with MP470 had more ds DNA damage than cells treated with radiation alone. Mechanistically, MP470 was shown to inhibit dsDNA break repair and increase apoptosis. MP470 influences various survival and DNA repair related proteins such as pAKT, RAD51 and GSK3β. In vivo, the addition of MP470 to radiation resulted in a tumor-growth-delay enhancement ratio of 2.9 over radiation alone and extended survival time.Conclusions: GBM is a disease site where radiation is often used to address both macroscopic and microscopic disease. Despite attempts at dose escalation outcomes remain poor. MP470, a potent small-molecule tyrosine kinase inhibitor of c-Met, radiosensitized several GBM cell lines both in vitro and in vivo, and may help to improve outcomes for patients with GBM.",
author = "Welsh, {James W.} and Daruka Mahadevan and Ron Ellsworth and Laurence Cooke and David Bearss and Baldassarre Stea",
year = "2009",
month = "12",
day = "22",
doi = "10.1186/1748-717X-4-69",
language = "English (US)",
volume = "4",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

AU - Welsh, James W.

AU - Mahadevan, Daruka

AU - Ellsworth, Ron

AU - Cooke, Laurence

AU - Bearss, David

AU - Stea, Baldassarre

PY - 2009/12/22

Y1 - 2009/12/22

N2 - Purpose: Glioblastoma multiforme (GBM) is resistant to current cytotoxic therapies, in part because of enhanced DNA repair. Activation of the receptor tyrosine kinase c-Met has been shown to protect cancer cells from DNA damage. We hypothesized that inhibiting c-Met would decrease this protection and thus sensitize resistant tumor cells to the effects of radiation therapy.Materials and methods: Eight human GBM cell lines were screened for radiosensitivity to the small-molecule c-Met inhibitor MP470 with colony-count assays. Double-strand (ds) DNA breaks was quantified by using antibodies to gamma H2AX. Western blotting demonstrate expression of RAD51, glycogen synthase kinase (GSK)-3β, and other proteins. A murine xenograft tumor flank model was used for in vivo radiosensitization studies.Results: MP470 reduced c-Met phosphorylation and enhanced radiation-induced cell kill by 0.4 logs in SF767 cells. Cells pretreated with MP470 had more ds DNA damage than cells treated with radiation alone. Mechanistically, MP470 was shown to inhibit dsDNA break repair and increase apoptosis. MP470 influences various survival and DNA repair related proteins such as pAKT, RAD51 and GSK3β. In vivo, the addition of MP470 to radiation resulted in a tumor-growth-delay enhancement ratio of 2.9 over radiation alone and extended survival time.Conclusions: GBM is a disease site where radiation is often used to address both macroscopic and microscopic disease. Despite attempts at dose escalation outcomes remain poor. MP470, a potent small-molecule tyrosine kinase inhibitor of c-Met, radiosensitized several GBM cell lines both in vitro and in vivo, and may help to improve outcomes for patients with GBM.

AB - Purpose: Glioblastoma multiforme (GBM) is resistant to current cytotoxic therapies, in part because of enhanced DNA repair. Activation of the receptor tyrosine kinase c-Met has been shown to protect cancer cells from DNA damage. We hypothesized that inhibiting c-Met would decrease this protection and thus sensitize resistant tumor cells to the effects of radiation therapy.Materials and methods: Eight human GBM cell lines were screened for radiosensitivity to the small-molecule c-Met inhibitor MP470 with colony-count assays. Double-strand (ds) DNA breaks was quantified by using antibodies to gamma H2AX. Western blotting demonstrate expression of RAD51, glycogen synthase kinase (GSK)-3β, and other proteins. A murine xenograft tumor flank model was used for in vivo radiosensitization studies.Results: MP470 reduced c-Met phosphorylation and enhanced radiation-induced cell kill by 0.4 logs in SF767 cells. Cells pretreated with MP470 had more ds DNA damage than cells treated with radiation alone. Mechanistically, MP470 was shown to inhibit dsDNA break repair and increase apoptosis. MP470 influences various survival and DNA repair related proteins such as pAKT, RAD51 and GSK3β. In vivo, the addition of MP470 to radiation resulted in a tumor-growth-delay enhancement ratio of 2.9 over radiation alone and extended survival time.Conclusions: GBM is a disease site where radiation is often used to address both macroscopic and microscopic disease. Despite attempts at dose escalation outcomes remain poor. MP470, a potent small-molecule tyrosine kinase inhibitor of c-Met, radiosensitized several GBM cell lines both in vitro and in vivo, and may help to improve outcomes for patients with GBM.

UR - http://www.scopus.com/inward/record.url?scp=74549159014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549159014&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-4-69

DO - 10.1186/1748-717X-4-69

M3 - Article

VL - 4

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 69

ER -